Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Biederstädt

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Blood|May 5, 2022
How I treat high-risk acute myeloid leukemia using preemptive adoptive cellular immunotherapyAlexander Biederstädt, Katayoun Rezvani
International Journal of Hematology|August 28, 2021
Engineering the next generation of CAR-NK immunotherapiesAlexander Biederstädt, Katayoun Rezvani
Cancer Cell|October 24, 2025
Engineered natural killer cells for cancer therapyAlexander Biederstädt, Katayoun Rezvani
Nature Reviews. Cancer|July 25, 2022
Natural killer cells in antitumour adoptive cell immunotherapyTamara J Laskowski, Alexander Biederstädt, Katayoun Rezvani
Frontiers in Immunology|December 9, 2022
Multiplexed engineering and precision gene editing in cellular immunotherapyAlexander Biederstädt, Gohar Shahwar Manzar, May Daher
Frontiers in Immunology|July 23, 2025
Allogeneic CAR-engineered cellular therapy for relapsed and refractory large B cell lymphoma: a systematic review and meta-analysisAlexander Biederstädt, Florian Bassermann, Judith S Hecker
Transfusion|April 11, 2024
Comparison of two autologous hematopoietic stem cell mobilization strategies in patients with multiple myeloma: CE plus G-CSF versus G-CSF only: A single-center retrospective analysisVeronika Dill, Philipp Blüm, Anja Lindemann, et al.
BMC Cancer|September 16, 2020
RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAVSylvie Lorenzen, Alexander Biederstädt, Ulrich Ronellenfitsch, et al.
Gut|February 1, 2020
SUMO pathway inhibition targets an aggressive pancreatic cancer subtypeAlexander Biederstädt, Zonera Hassan, Christian Schneeweis, et al.
Nature Medicine|September 29, 2022
KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escapeYe Li, Rafet Basar, Guohui Wang, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Blood|May 5, 2022
How I treat high-risk acute myeloid leukemia using preemptive adoptive cellular immunotherapyAlexander Biederstädt, Katayoun Rezvani
International Journal of Hematology|August 28, 2021
Engineering the next generation of CAR-NK immunotherapiesAlexander Biederstädt, Katayoun Rezvani
Cancer Cell|October 24, 2025
Engineered natural killer cells for cancer therapyAlexander Biederstädt, Katayoun Rezvani
Nature Reviews. Cancer|July 25, 2022
Natural killer cells in antitumour adoptive cell immunotherapyTamara J Laskowski, Alexander Biederstädt, Katayoun Rezvani
Frontiers in Immunology|December 9, 2022
Multiplexed engineering and precision gene editing in cellular immunotherapyAlexander Biederstädt, Gohar Shahwar Manzar, May Daher
Frontiers in Immunology|July 23, 2025
Allogeneic CAR-engineered cellular therapy for relapsed and refractory large B cell lymphoma: a systematic review and meta-analysisAlexander Biederstädt, Florian Bassermann, Judith S Hecker
Transfusion|April 11, 2024
Comparison of two autologous hematopoietic stem cell mobilization strategies in patients with multiple myeloma: CE plus G-CSF versus G-CSF only: A single-center retrospective analysisVeronika Dill, Philipp Blüm, Anja Lindemann, et al.
BMC Cancer|September 16, 2020
RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAVSylvie Lorenzen, Alexander Biederstädt, Ulrich Ronellenfitsch, et al.
Gut|February 1, 2020
SUMO pathway inhibition targets an aggressive pancreatic cancer subtypeAlexander Biederstädt, Zonera Hassan, Christian Schneeweis, et al.
Nature Medicine|September 29, 2022
KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escapeYe Li, Rafet Basar, Guohui Wang, et al.
Pageof 2